KPTI: Karyopharm Therapeutics Inc. Stocks News on June 2, 2025

KPTI

Zacks

7 days ago

Here's Why Karyopharm Therapeutics (KPTI) Is a Great 'Buy the Bottom' Stock Now

KPTI

Zacks

14 days ago

Does Karyopharm Therapeutics (KPTI) Have the Potential to Rally 521.62% as Wall Street Analysts Expect?

Karyopharm to Participate at the 2025 RBC Capital Markets Global Healthcare Conference

KPTI

PR Newswire

14 days ago

Karyopharm to Participate at the 2025 RBC Capital Markets Global Healthcare Conference

Karyopharm Announces Poster Presentation on Selinexor in Myelofibrosis at the 2025 European Hematology Association Annual Meeting

KPTI

PR Newswire

19 days ago

Karyopharm Announces Poster Presentation on Selinexor in Myelofibrosis at the 2025 European Hematology Association Annual Meeting

KPTI

MT Newswires

20 days ago

RBC Adjusts Price Target on Karyopharm Therapeutics to $33 From $43, Maintains Outperform Rating

KPTI

GuruFocus.com

20 days ago

Karyopharm Therapeutics Inc (KPTI) Q1 2025 Earnings Call Highlights: Promising Clinical ...

KPTI

Zacks

21 days ago

Karyopharm Therapeutics (KPTI) Reports Q1 Loss, Lags Revenue Estimates

KPTI

Associated Press Finance

21 days ago

Karyopharm Therapeutics: Q1 Earnings Snapshot

Karyopharm Reports First Quarter 2025 Financial Results and Announces New Data in Myelofibrosis that Further Suggests Selinexor May Lead to Meaningful Spleen Volume Reduction, Symptom Improvement, Hemoglobin Stabilization and Disease Modification

KPTI

PR Newswire

21 days ago

Karyopharm Reports First Quarter 2025 Financial Results and Announces New Data in Myelofibrosis that Further Suggests Selinexor May Lead to Meaningful Spleen Volume Reduction, Symptom Improvement, Hemoglobin Stabilization and Disease Modification

Karyopharm to Report First Quarter 2025 Financial Results on May 12, 2025

KPTI

PR Newswire

25 days ago

Karyopharm to Report First Quarter 2025 Financial Results on May 12, 2025

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KPTI

PR Newswire

a month ago

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KPTI

MT Newswires

2 months ago

RBC Lowers Price Target on Karyopharm Therapeutics to $43 From $45, Keeps Outperform Rating

KPTI

PR Newswire

2 months ago

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Biotech stocks slide as Marks resignation seen being negative for sector

KPTI

TipRanks

2 months ago

Biotech stocks slide as Marks resignation seen being negative for sector

KPTI

PR Newswire

3 months ago

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KPTI

MT Newswires

3 months ago

Karyopharm Therapeutics to Implement 1-for-15 Reverse Stock Split

Karyopharm Announces 1-for-15 Reverse Stock Split

KPTI

PR Newswire

3 months ago

Karyopharm Announces 1-for-15 Reverse Stock Split

Karyopharm Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

KPTI

Simply Wall St.

3 months ago

Karyopharm Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

KPTI

GuruFocus.com

3 months ago

Karyopharm Therapeutics Inc (KPTI) Q4 2024 Earnings Call Highlights: Navigating Revenue ...

KPTI

Thomson Reuters StreetEvents

3 months ago

Q4 2024 Karyopharm Therapeutics Inc Earnings Call

KPTI

Motley Fool

3 months ago

Karyopharm Therapeutics (KPTI) Q4 2024 Earnings Call Transcript

KPTI

Zacks

3 months ago

Karyopharm Therapeutics (KPTI) Reports Q4 Loss, Tops Revenue Estimates

KPTI

Associated Press Finance

3 months ago

Karyopharm Therapeutics: Q4 Earnings Snapshot

Karyopharm Reports Fourth Quarter and Full Year 2024 Financial Results, Announces Update to Phase 3 XPORT-EC-042 Trial and Highlights Recent Company Progress

KPTI

PR Newswire

3 months ago

Karyopharm Reports Fourth Quarter and Full Year 2024 Financial Results, Announces Update to Phase 3 XPORT-EC-042 Trial and Highlights Recent Company Progress

KPTI

GuruFocus.com

3 months ago

Karyopharm Therapeutics Inc (KPTI) Q4 2024 Earnings Report Preview: What To Look For

Analysts Estimate Indivior PLC (INDV) to Report a Decline in Earnings: What to Look Out for

KPTI

Zacks

4 months ago

Analysts Estimate Indivior PLC (INDV) to Report a Decline in Earnings: What to Look Out for

Karyopharm to Report Fourth Quarter and Full Year 2024 Financial Results on February 19, 2025

KPTI

PR Newswire

4 months ago

Karyopharm to Report Fourth Quarter and Full Year 2024 Financial Results on February 19, 2025

KPTI

PR Newswire

4 months ago

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Verve Therapeutics (VERV) Moves 18.7% Higher: Will This Strength Last?

KPTI

Zacks

4 months ago

Verve Therapeutics (VERV) Moves 18.7% Higher: Will This Strength Last?

Karyopharm Announces Preliminary Unaudited 2024 Revenue and 2025 Objectives

KPTI

PR Newswire

5 months ago

Karyopharm Announces Preliminary Unaudited 2024 Revenue and 2025 Objectives

KPTI

Insider Monkey

5 months ago

Why Karyopharm Therapeutics (KPTI) Is Among the Best Penny Stocks to Invest In According to Media?

KPTI

PR Newswire

5 months ago

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KPTI

MT Newswires

5 months ago

Karyopharm Therapeutics Names Lori Macomber CFO

Karyopharm Announces the Appointment of Lori Macomber as Chief Financial Officer

KPTI

PR Newswire

5 months ago

Karyopharm Announces the Appointment of Lori Macomber as Chief Financial Officer

Karyopharm Announces the Appointment of Brendan Strong as Senior Vice President of Investor Relations and Corporate Communications

KPTI

PR Newswire

6 months ago

Karyopharm Announces the Appointment of Brendan Strong as Senior Vice President of Investor Relations and Corporate Communications

Karyopharm Therapeutics Provides Endometrial Cancer Program Update

KPTI

PR Newswire

6 months ago

Karyopharm Therapeutics Provides Endometrial Cancer Program Update

KPTI

PR Newswire

6 months ago

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Karyopharm to Participate at the Piper Sandler 36th Annual Healthcare Conference

KPTI

PR Newswire

6 months ago

Karyopharm to Participate at the Piper Sandler 36th Annual Healthcare Conference

KPTI

MT Newswires

6 months ago

Karyopharm Therapeutics Appoints Kristin Abate as Chief Accounting Officer

Karyopharm Therapeutics Announces the Appointment of Chief Accounting Officer

KPTI

PR Newswire

6 months ago

Karyopharm Therapeutics Announces the Appointment of Chief Accounting Officer

Karyopharm to Present Selinexor Data at the 66th American Society of Hematology Annual Meeting and Exposition

KPTI

PR Newswire

6 months ago

Karyopharm to Present Selinexor Data at the 66th American Society of Hematology Annual Meeting and Exposition

KPTI

Simply Wall St.

7 months ago

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Karyopharm Therapeutics Third Quarter 2024 Earnings: Beats Expectations

KPTI

Simply Wall St.

7 months ago

Karyopharm Therapeutics Third Quarter 2024 Earnings: Beats Expectations

KPTI

GuruFocus.com

7 months ago

Karyopharm Therapeutics Inc (KPTI) Q3 2024 Earnings Call Highlights: Navigating Growth Amidst ...

KPTI

Motley Fool

7 months ago

Karyopharm Therapeutics (KPTI) Q3 2024 Earnings Call Transcript

KPTI

Zacks

7 months ago

Karyopharm Therapeutics (KPTI) Reports Q3 Loss, Tops Revenue Estimates

KPTI

Associated Press Finance

7 months ago

Karyopharm Therapeutics: Q3 Earnings Snapshot

Karyopharm Reports Third Quarter 2024 Financial Results and Highlights Recent Company Progress

KPTI

PR Newswire

7 months ago

Karyopharm Reports Third Quarter 2024 Financial Results and Highlights Recent Company Progress

KPTI

GuruFocus.com

7 months ago

Karyopharm Therapeutics Inc (KPTI) Q3 2024: Everything You Need To Know Ahead Of Earnings

KPTI

PR Newswire

7 months ago

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Earnings Preview: Amneal Pharmaceuticals (AMRX) Q3 Earnings Expected to Decline

KPTI

Zacks

7 months ago

Earnings Preview: Amneal Pharmaceuticals (AMRX) Q3 Earnings Expected to Decline

KPTI

Zacks

7 months ago

Karyopharm Therapeutics (KPTI) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Karyopharm to Report Third Quarter 2024 Financial Results on November 5, 2024

KPTI

PR Newswire

7 months ago

Karyopharm to Report Third Quarter 2024 Financial Results on November 5, 2024

Karyopharm Announces Favorable Change in Co-Primary Endpoint for Pivotal Phase 3 SENTRY Trial in Myelofibrosis

KPTI

PR Newswire

7 months ago

Karyopharm Announces Favorable Change in Co-Primary Endpoint for Pivotal Phase 3 SENTRY Trial in Myelofibrosis

Karyopharm to Host Investor Event with Leading Myelofibrosis KOLs and Provide a Favorable Study Design Update on October 31, 2024

KPTI

PR Newswire

7 months ago

Karyopharm to Host Investor Event with Leading Myelofibrosis KOLs and Provide a Favorable Study Design Update on October 31, 2024

Highbridge Capital Management's Strategic Acquisition of Karyopharm Therapeutics Shares

KPTI

GuruFocus.com

7 months ago

Highbridge Capital Management's Strategic Acquisition of Karyopharm Therapeutics Shares

KPTI

PR Newswire

8 months ago

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KPTI

Zacks

9 months ago

Down -12.14% in 4 Weeks, Here's Why Karyopharm Therapeutics (KPTI) Looks Ripe for a Turnaround

KPTI

PR Newswire

9 months ago

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Karyopharm to Participate at Upcoming Investor Conferences

KPTI

PR Newswire

9 months ago

Karyopharm to Participate at Upcoming Investor Conferences

Pipeline Moves: Investigator-led oncology cell therapy trial terminated

KPTI

Clinical Trials Arena

9 months ago

Pipeline Moves: Investigator-led oncology cell therapy trial terminated

KPTI

Simply Wall St.

10 months ago

With 58% ownership, Karyopharm Therapeutics Inc. (NASDAQ:KPTI) boasts of strong institutional backing

KPTI

Thomson Reuters StreetEvents

10 months ago

Q2 2024 Karyopharm Therapeutics Inc Earnings Call

KPTI

Motley Fool

10 months ago

Karyopharm Therapeutics (KPTI) Q2 2024 Earnings Call Transcript

KPTI

Zacks

10 months ago

Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Tops Revenue Estimates

KPTI

Associated Press Finance

10 months ago

Karyopharm Therapeutics: Q2 Earnings Snapshot

Karyopharm Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress

KPTI

PR Newswire

10 months ago

Karyopharm Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress

KPTI

PR Newswire

10 months ago

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Karyopharm to Report Second Quarter 2024 Financial Results on August 6, 2024

KPTI

PR Newswire

10 months ago

Karyopharm to Report Second Quarter 2024 Financial Results on August 6, 2024

Earnings Preview: Assertio (ASRT) Q2 Earnings Expected to Decline

KPTI

Zacks

10 months ago

Earnings Preview: Assertio (ASRT) Q2 Earnings Expected to Decline

KPTI

Insider Monkey

10 months ago

Karyopharm Therapeutics Inc. (KPTI): Is This One-Dollar Stock a Strong Buy Right Now?

KPTI

Insider Monkey

a year ago

Karyopharm Therapeutics Inc. (KPTI): Is This Penny Stock A Good Buy Right Now?

KPTI

PR Newswire

a year ago

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KPTI

MT Newswires

a year ago

HC Wainwright Adjusts Price Target on Karyopharm Therapeutics to $7 From $8, Maintains Buy Rating

KPTI

PR Newswire

a year ago

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract Updates

KPTI

PR Newswire

a year ago

Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract Updates

Karyopharm to Participate at the Jefferies Global Healthcare Conference

KPTI

PR Newswire

a year ago

Karyopharm to Participate at the Jefferies Global Healthcare Conference

Karyopharm Therapeutics First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

KPTI

Simply Wall St.

a year ago

Karyopharm Therapeutics First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

KPTI

Insider Monkey

a year ago

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q1 2024 Earnings Call Transcript

KPTI

GuruFocus.com

a year ago

Karyopharm Therapeutics Inc (KPTI) Q1 2024 Earnings Call Transcript Highlights: Navigating ...

KPTI

Thomson Reuters StreetEvents

a year ago

Q1 2024 Karyopharm Therapeutics Inc Earnings Call

KPTI

Motley Fool

a year ago

Karyopharm Therapeutics (KPTI) Q1 2024 Earnings Call Transcript

Karyopharm to Participate at the 2024 RBC Capital Markets Global Healthcare Conference

KPTI

PR Newswire

a year ago

Karyopharm to Participate at the 2024 RBC Capital Markets Global Healthcare Conference

KPTI

GuruFocus.com

a year ago

Karyopharm Therapeutics Reports Q1 2024 Financial Results: A Detailed Review

KPTI

Associated Press Finance

a year ago

Karyopharm Therapeutics: Q1 Earnings Snapshot

Karyopharm Announces Significant Refinancing Transactions and Amended Royalty Agreement Extending Vast Majority of Its Debt Maturities into 2028 and 2029

KPTI

PR Newswire

a year ago

Karyopharm Announces Significant Refinancing Transactions and Amended Royalty Agreement Extending Vast Majority of Its Debt Maturities into 2028 and 2029

Karyopharm Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress

KPTI

PR Newswire

a year ago

Karyopharm Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress

Karyopharm to Report First Quarter 2024 Financial Results on May 8, 2024

KPTI

PR Newswire

a year ago

Karyopharm to Report First Quarter 2024 Financial Results on May 8, 2024

KPTI

PR Newswire

a year ago

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Karyopharm Announces Presentations in Endometrial Cancer and Myelofibrosis at the 2024 American Society of Clinical Oncology Annual Meeting

KPTI

PR Newswire

a year ago

Karyopharm Announces Presentations in Endometrial Cancer and Myelofibrosis at the 2024 American Society of Clinical Oncology Annual Meeting

KPTI

PR Newswire

a year ago

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Karyopharm to Participate at Barclays 26th Annual Global Healthcare and Leerink Partners Global Biopharma Conferences

KPTI

PR Newswire

a year ago

Karyopharm to Participate at Barclays 26th Annual Global Healthcare and Leerink Partners Global Biopharma Conferences

Insider Sell: President and CEO Richard Paulson Sells 99,844 Shares of Karyopharm Therapeutics ...

KPTI

GuruFocus.com

a year ago

Insider Sell: President and CEO Richard Paulson Sells 99,844 Shares of Karyopharm Therapeutics ...

KPTI

PR Newswire

a year ago

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KPTI

Insider Monkey

a year ago

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q4 2023 Earnings Call Transcript

KPTI

Thomson Reuters StreetEvents

a year ago

Q4 2023 Karyopharm Therapeutics Inc Earnings Call

KPTI

Motley Fool

a year ago

Karyopharm Therapeutics (KPTI) Q4 2023 Earnings Call Transcript

KPTI

Zacks

a year ago

Karyopharm Therapeutics (KPTI) Reports Q4 Loss, Tops Revenue Estimates

KPTI

Associated Press Finance

a year ago

Karyopharm Therapeutics: Q4 Earnings Snapshot

Karyopharm Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress

KPTI

PR Newswire

a year ago

Latest Karyopharm Therapeutics Inc. (KPTI) News on June 2, 2025

Share on Social Networks: